H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Aptinyx (APTX) today and set a price target of $8.00. The company’s shares closed last Wednesday at $3.36.
According to TipRanks.com, Selvaraju is a 4-star analyst with an average return of 12.8% and a 51.1% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Protalix Biotherapeutics, EyePoint Pharmaceuticals, and Bausch Health Companies.
Aptinyx has an analyst consensus of Strong Buy, with a price target consensus of $10.67.
See today’s analyst top recommended stocks >>
Aptinyx’s market cap is currently $229.1M and has a P/E ratio of -3.90. The company has a Price to Book ratio of 1.60.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Aptinyx Inc. is a clinical stage biopharmaceutical company. It engages in the discovery, development, and and commercialization of transformative therapies for disorders of the brain and nervous system. Its product includes NYX-2925, NYX-783, NYX-458, and the AGN-241751 program. The company was founded by Norbert G. Riedel and Joseph R. Moskal in June 2015 and is headquartered in Evanston, IL.
Read More on APTX:
